

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

PETRY, S. et. al.

BALASUBRAMANIAN, VENKATARAMAN

Application No.: **10/760,509**

Art Unit: **1624**

Filed: **January 20, 2004**

Title: **Pyrimido[5,4-E][1,2,4]Triazine-5,7-Diones,
Process for Preparing them and their use**

<p align="center">Certificate of Mailing or Transmission</p> <p>I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage for first class mail in an envelope addressed to the Mail Stop address below, or being facsimile transmitted to the USPTO, on the date indicated below.</p> <p>Date of Deposit <u>August 25, 2005</u></p> <p>Printed Name of Person Signing Certificate <u>Brian Pritchett</u></p> <p>Signature <u>Brian Pritchett</u></p>
--

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
FOR WHICH THE FEE SPECIFIED UNDER 37 C.F.R. 1.97(c) IS REQUIRED**

Mail Stop
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Enclosed is an Information Disclosure Statement for which the fee specified in 37 C.F.R. 1.97(c) is required.

Please charge Deposit Account No. **18-1982** in the amount of \$180.00. Two duplicate copies of this sheet are enclosed. The Commissioner is authorized to charge any fees under 37 C.F.R. 1.17(p) or credit any overpayment to Account No. **18-1982**.

Respectfully submitted,

Barbara E. Kurys, Reg. No. 34,650
Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, NJ 08807-0800
Telephone (908) 231-2965
Telefax (908) 231-2626

Aventis Docket No. DEAV2003/0003 US NP



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

PETRY, S. et. al.

Examiner:

BALASUBRAMANIAN, VENKATARAMAN

Application No.: **10/760,509**

Art Unit: **1624**

Filed: **January 20, 2004**

Title: **Pyrimido[5,4-E][1,2,4]Triazine-5,7-Diones,
Process for Preparaing them and their
use**

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

August 23, 2005
Date of Deposit

Brian Pritchett
Signature

INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. 1.56, 1.97 AND 1.98

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Applicants submit herewith patents, publications, and other information of which they are aware, which they believe may be material, as defined in 37 C.F.R. 1.56(b), to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 C.F.R. 1.56(a). While the information referred to in this Information Disclosure Statement may be material pursuant to 37 C.F.R. 1.56(b), the filing of this Information Disclosure Statement is not intended to, pursuant to 37 C.F.R. 1.97(h), constitute an admission that any patent, publication or other information referred to is, or is considered to be, material to the patentability of this invention. Pursuant to 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information exists.


- ☒ (a) This Information Disclosure Statement is filed within the period set forth in §1.97(b) because it accompanies the new patent application submitted herewith, is filed within three months of the filing date of a national application or within three months of the date of entry of the national stage as set forth in §1.491 in an international application, or is believed to be filed before the mailing date of a first Office Action on the merits, whichever event occurs last. However, in the event that the first office action has been mailed, the Commissioner is authorized to charge any fees under 37 C.F.R. 1.17(p) or credit any overpayment to Account No. 18-1982.

08/26/2005 RFEKADU1 00000026 181982 10760509

02 FC:1806 180.00 DA

- ☐ (b) This Information Disclosure Statement is filed after the period set forth in 37 C.F.R. 1.97(b), but is believed to be filed before the mailing date of a final action under §1.113 or a notice of allowance under §1.311, whichever occurs first.
- ☐ (1) The undersigned attorney certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement;
- ☐ (2) The undersigned attorney certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned attorney after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of this statement; or
- ☐ (3) This Information Disclosure Statement is accompanied by a transmittal letter in which payment of the fee set forth in §1.17(p) and required by 37 C.F.R. 1.97(c) is authorized.

Respectfully submitted,



Barbara E. Kurys, Reg. No. 34,650
Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, NJ 08807-0800
Telephone (908) 231-2965
Telefax (908) 231-2626
Aventis Docket No. DEAV2003/0003 US NP

PATENT & TRADEMARK OFFICE

☒

Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known

(use as many sheets as necessary)

Application Number	10/760,509
Filing Date	01-20-2004
First Named Inventor	PETRY
Group Art Unit	1624
Examiner Name	BALASUBRAMANIAN, Venkataraman
Attorney Docket Number	DEAV2003/0003 - US - NP

[illegible]

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
		WO	00/40569		HODSON, et. al.	07-13-2000		
		WO	00/64876		JAYYOSI, et. al.	11-02-2000		
		WO	00/66585		HORVATH, et. al.	11-09-2000		
		WO	00/71549		BROUGH, et. al.	11-30-2000		
		WO	01/09111		BRINER, et. al.	02-08-2001		
		WO	01/83451		IKUTA, et. al.	11-08-2001		
		WO	97/26265		NIELSEN, et. al.	07-24-1997		
		WO	97/41097		LOHRAY, et. al.	11-06-1997		
		WO	98/08871		KNUDSEN, et. al.	03-05-1998		
		WO	99/03861		NIELSEN, et. al.	01-28-1999		

Date
Considered

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**

☒

+

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/760,509
				Filing Date	01-20-2004
				First Named Inventor	PETRY
				Group Art Unit	1624
				Examiner Name	BALASUBRAMANIAN, Venkataraman
Sheet	2	of	4	Attorney Docket Number	DEAV2003/0003 - US - NP

[illegible][illegible]

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

+

Please type a plus sign (+) inside this box → ☒

PTO/SB/08B (10-96)

Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO			Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Application Number	10/760,509
			Filing Date	01-20-2004
			First Named Inventor	PETRY
			Group Art Unit	1624
			Examiner Name	BALASUBRAMANIAN, Venkataraman
			Attorney Docket Number	DEAV2003/0003 - US - NP
Sheet	3	of	4	

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		ASAKAWA, A., et. al., Cocaine-Amphetamine-Regulated Transcript Influences Energy Metabolism, Anxiety and Gastric Emptying in Mice, Hormone and Metabolic Research, (2001) Vol. 33, No. 9, pp. 554 - 558	
		LEE, D. W., et. al., Leptin agonists as a potential approach to the treatment of obesity, Drugs of the Future, 2001, Vol. 26(9), pp 873-881	
		LIOA, T., et. al., Synthesis of 1-Demethyltoxoflavin (8-Demethylferavenulin)1, Journal of Organic Chemistry, Vol. 31, (1965) pp. 900-902	
		TONKS, N.K., et. al., Characterization of the Major Protein-tyrosine-phosphatases of Human Placenta, Journal of Biological Chemistry, Vol. 263, No. 14, May 15, 1988, pp. 6731-6737	
		OKADA, H., et. al., Synthesis and Antitumor Activities of Prodrugs of Benzoylphenylureas, Chem. Pharm. Bull., (1994), Vol. 42, No. 1, pp. 57 - 61	
		TYLE, P., et. al., Ionophoretic Devices for Drug Delivery, Pharmaceutical Research, Vol. 3, No. 6, 1986	
		LANZETTA, P.A., et. al., An Improved Assay for Nanomole Amounts of Inorganic Phosphate, Analytical Biochemistry, Vol. 100, 1979, pp. 95-97	
		SALVADOR, J., et. al., Perspectives in the therapeutic use of leptin, Expert Opinion on Pharmacotherapy 2001, 2(10), 1615-1622	
		BURKE, T.R., et. al., Small Molecule Interactions with Protein-Tyrosine Phosphatase PTP1B and Their Use in Inhibitor Design, Biochemistry, Vol. 35, 1996, pp. 15989-15996	
		CROMLISH, W., et. al., Selective Inhibition of Cyclooxygenase-1 and -2 Using Intact Insect Cell Assays, Biochemical Pharmacology, Vol 52, 1996, pp. 1777-1785	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☒

+

PTO/SB/08B (10-96)

Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	10/760,509
				Filing Date	01-20-2004
				First Named Inventor	PETRY
				Group Art Unit	1624
				Examiner Name	BALASUBRAMANIAN, Venkataraman
Sheet	4	of	4	Attorney Docket Number	DEAV2003/0003 - US - NP

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		YONEDA, F., et. al., Antitumor Agent, Patent Abstracts of Japan Vol. 1998-01-30	
		YONEDA, F., et. al., A Convenient Synthesis of Toxoflavins, Toxoflavin 4-Oxides and 1-Demethyltoxoflavins, Chemical and Pharmaceutical Bulletin Vol.23, No.9 (1975) pp. 2001-2009	
		ZUNFT, H., et. al., Carob Pulp Preparation for Treatment of Hypercholesterolemia, Advances in Therapy, 2001, Vol. 18(5), pp 230-236	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+